摘要
汉康医药由研发起步,经十几年努力,现已成为集研发、生产、销售于一体的研发驱动型集团化企业。公司近八年在国内新药申报排行榜排名前十,获临床批件81件,新药证书25件,发明专利证书62项,荣获＂中国医药工业最具投资价值企业（非上市）＂称号,创始人兼董事长严洁女士亦被授予国家创新创业人才荣誉。现有2个全资子公司：天津汉瑞药业有限公司和天津泽普瑞医药科技有限公司。
Objective To observe the serum protamine 1 （PRM1） content and its expression in cancerous tissue of colonic carcinoma patients, and to explore its clinical significance. Methods The serum PRM1 levels in colon cancer patients （n=60） and healthy subjects （n=60）were tested by ELISA test. PRM1 expression in colorectal cancer tissue were tested by immunohistochemical experiment testing. Results The serum PRM1 levels of colon cancer patients were significantly higher than those of healthy controls （P 〈 0.01）. The PRM1 positive rate was 86.7% （52/60） in colon cancer patients. Conclusion RRM1 may be used as a sensitive index of colon cancer, which plays an important role in molecular diagnosis or immune therapy.
作者
张科
王晓光
闫金银
ZHANG Ke, WANG Xiao-guang, YAN Jin-yin（ Department of General Surgery, Tangshan Traditional Chinese Medicine Hospital, Tangshan 063000 2. Department of Qncology, Tangshan People＇s Hospital, Tangshan 063000, China）
出处
《世界临床药物》
CAS
2015年第10期693-695,共3页
World Clinical Drug
